CytoDyn Inc.
CYDY
$0.35
$0.038.84%
OTC PK
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.30% | -29.27% | -24.24% | -32.76% | -19.54% |
| Depreciation & Amortization | 44.00% | 22.22% | -40.00% | -- | -171.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.78% | 17.25% | 10.80% | -15.14% | 11.10% |
| Operating Income | -26.78% | -17.25% | -10.80% | 15.14% | -11.10% |
| Income Before Tax | -447.46% | -172.75% | -10.39% | 107.51% | 86.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -447.46% | -172.75% | -10.39% | 107.51% | 86.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -447.46% | -172.75% | -10.39% | 107.51% | 86.29% |
| EBIT | -26.78% | -17.25% | -10.80% | 15.14% | -11.10% |
| EBITDA | -26.81% | -17.28% | -10.86% | 15.10% | -11.24% |
| EPS Basic | -267.82% | -89.41% | 21.55% | 105.88% | 84.63% |
| Normalized Basic EPS | 0.00% | 23.49% | 34.34% | 44.79% | 47.37% |
| EPS Diluted | -291.40% | -107.95% | 12.61% | 99.81% | 83.57% |
| Normalized Diluted EPS | -0.78% | 22.97% | 33.94% | 45.31% | 47.77% |
| Average Basic Shares Outstanding | 9.35% | 14.45% | 20.83% | 24.38% | 21.71% |
| Average Diluted Shares Outstanding | 7.86% | 12.81% | 18.99% | 26.01% | 23.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |